Innovative blood treatment developed in Cork could prevent blockages leading to amputations

UCC spinout company has been awarded €2.5m grant through Enterprise Ireland

Professor Noel Caplice, ProVascTec chief scientific officer and chair of cardiovascular sciences at UCC. Picture: Tomas Tyner, UCC.

A new product designed in Cork to restore blood flow to the extremities following an arterial blockage has been awarded a €2.5m grant through Enterprise Ireland. 

Developed by University College Cork spin-out company ProVascTec, PulseCLTI is a cell therapy which will treat patients suffering from critical limb ischemia - a severe blockage in the arteries that can lead to amputation or limb loss. It has been backed with a research grant from the Enterprise Ireland Disruptive Technologies Innovation Fund (DTIF).